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Abstract
Background: Enterococci are a major cause of healthcare-associated infection. In Australia, vanB vancomycin-resistant
enterococci (VRE) is the predominant genotype. There are limited data on the factors linked to vanB VRE bacteraemia.
This study aimed to identify factors associated with vanB VRE bacteraemia, and compare them with those for
vancomycin-susceptible enterococci (VSE) bacteraemia.
Methods: A case-case-control study was performed in two tertiary public hospitals in Victoria, Australia. VRE and VSE
bacteraemia cases were compared with controls without evidence of enterococcal bacteraemia, but may have had
infections due to other pathogens.
Results: All VRE isolates had vanB genotype. Factors associated with vanB VRE bacteraemia were urinary catheter use
within the last 30 days (OR 2.86, 95% CI 1.09-7.53), an increase in duration of metronidazole therapy (OR 1.65, 95% CI
1.17-2.33), and a higher Chronic Disease Score specific for VRE (OR 1.70, 95% CI 1.05-2.77). Factors linked to VSE
bacteraemia were a history of gastrointestinal disease (OR 2.29, 95% CI 1.05-4.99) and an increase in duration of
metronidazole therapy (OR 1.23, 95% CI 1.02-1.48). Admission into the haematology/oncology unit was associated with
lower odds of VSE bacteraemia (OR 0.08, 95% CI 0.01-0.74).
Conclusions: This is the largest case-case-control study involving vanB VRE bacteraemia. Factors associated with the
development of vanB VRE bacteraemia were different to those of VSE bacteraemia.
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Background
Globally, enterococci are a major cause of nosocomial
infection [1-3]. Of concern is vancomycin-resistant en-
terococci (VRE) bacteraemia, which has been associated
with higher mortality and morbidity compared to VRE
wound, urinary tract and intra-abdominal infections [4].
In Australia, vanB is the major genotype [3,5], in con-
trast to the United States (US) where vanA is predomin-
ant [2,6]. Importantly, VRE is increasingly isolated in
clinical settings [3], and has emerged in the community
viz. aged-care facilities and outpatient clinics [7,8].
Studies which examined the factors associated with
VRE colonisation and/or a range of different VRE infec-
tions have either had vanA genotype as the predominant
strain (as reported or through personal communication
with the authors) [9-14], or did not report the genotype
[4,15-29]. All aforementioned studies were performed in
the US, where vanA is predominant [2]. Only two stud-
ies examining factors linked to the development of VRE
bacteraemia involved predominantly the vanB genotype
[30,31]. The clinical profile of a colonised versus an in-
fected patient is different [32]. Thus, studies [4,23,25-27]
that have included both colonised and infected patients
as their VRE cases should be interpreted with care.
Case–control studies [4,11-14,16,17,19,25] comparing
VRE to VSE bacteraemia patients may not accurately
account for the impact of vancomycin use; this bias is
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minimised with a case-case-control study that compares
VRE bacteraemia patients to controls without enterococ-
cal bacteraemia and VSE bacteraemia patients to con-
trols [33]. Of the two studies involving predominantly
vanB genotype [30,31], only one [31] was a case-case-
control study which used the same control patients for
both case groups, thereby enabling meaningful charac-
terisation of the distinct features of bacteraemia specific
to the resistant and susceptible enterococci [33]. How-
ever, the external validity of the results from this single
centre study is limited [31]. Furthermore, that study [31]
and another involving vanA VRE [12] do not adjust for
patient co-morbidities, and duration of hypoalbuminae-
mia and neutropenia. Other studies [4,9-11,13-30] did
not adjust for a combination of factors (co-morbidities
and/or duration of antibiotic therapy, hypoalbuminae-
mia, and/or neutropenia).
Studies have found that neutropenia, use of antibiotics
(e.g. cephalosporins, imipenem and metronidazole),
urinary catheter and central venous catheter use, older
age, gastrointestinal disease, biliary complications, severe
mucositis, a higher severity of illness score and low
plasma albumin levels were linked to VSE bacteraemia
[31,34-40]. Unfortunately, the majority of these studies
on factors linked to VSE bacteraemia were descriptive
(had small sample size) [34-37], and did not adjust for
duration of antibiotic therapy, hypoalbuminaemia and/or
neutropenia [31,38,39].
Given that enterococcal bacteraemia is increasing and
data on factors linked to vanB VRE bacteraemia remain
limited, an understanding of the factors associated with
vanB VRE and VSE bacteraemia would facilitate efforts to
prevent and manage these infections. Thus, the primary
aim of this study was to identify the potential factors associ-
ated with vanB VRE bacteraemia and secondarily, to com-
pare them with those for VSE bacteraemia.
Methods
A retrospective case-case-control study was conducted
at two tertiary public hospitals, The Alfred (~420 acute-
care beds) and Austin Health (~400 acute-care beds) in
Victoria, Australia. Both institutions service adult pa-
tients, have intensive care units and emergency depart-
ments, infectious diseases and infection control units,
haematology-oncology services and provide other spe-
cialist services. This study was approved by the Human
Research Ethics Committees of both hospitals and Monash
University. Waiver of patient consent was approved by all
ethics committees because no patient recruitment of
follow-up occurred, and data utilised in this study included
information already collected as part of patient care.
All study participants were admitted to the hospital
between January 2002 and March 2010 (inclusive). The
sample size was based around all cases of VRE bacteraemia
identified during the study period. The study period was
specified a priori, from January 2002 to March 2010, as the
infection control interventions against VRE in both hospi-
tals did not change substantially over this time period. Only
patients with hospital length of stay (LOS) > 2 days were
eligible for inclusion in the study. Pregnant patients and
those < 18 years of age were excluded. Selection of all pa-
tients was made without knowledge of patient outcomes.
Each patient was only included once. Patients from whom
one or more blood cultures were positive for VRE were
classified as VRE cases. The VRE genotype was determined
by polymerase chain reaction [5,41]. Patients who had one
or more blood cultures positive for VSE were also identified
(VSE cases). Controls without evidence of enterococcal
bacteraemia were identified from a list of patients admitted
to the hospital and may have had infections (including bac-
teraemia) due to other pathogens. Matching was performed
within the same hospital on a 1:1:1 basis. VSE cases and
controls were matched with VRE cases according to date of
admission (within 2 years of VRE case admission date), and
where possible, unit of admission. Where more than one
VSE case or control was eligible for matching on the same
admission date, the VSE case or control was randomly
chosen.
The present analysis included additional data (e.g. pa-
tient co-morbidities, and duration of hypoalbuminaemia
and neutropenia) which were not considered in the
study discussed above [31] and patients from another
hospital. Information on patient demographics and clin-
ical characteristics, antimicrobial use, and outcomes of
hospitalisation were collected via a retrospective review
of patients’ medical records by the same researcher
(ALYC). These criteria for the exposure and outcome
measures were pre-determined prior to data collection.
Polymicrobial bacteraemia was the isolation of one or
more bacterial or fungal pathogens within 24 hours from
the same or different blood sample where the initial VRE or
VSE was isolated [17]. Chronic Disease Score specific to
VRE (CDS-VRE), which has been validated for use in stud-
ies on factors linked to disease, was used to measure patient
co-morbidities [42]. Gastrointestinal disease included a
history of liver disease, peptic ulcers, diverticulitis, graft-
versus-host-disease of the gut, inflammatory bowel disease,
colon cancer and colorectal cancer. Neutropenia, hypoalbu-
minaemia, exposure to medical devices, and antibiotic-
specific days were defined, respectively, as number of days
where neutrophils were < 500/mm3, serum or plasma albu-
min < 35 g/L, exposure to central lines, mechanical ventila-
tion, urinary catheter and total parenteral nutrition, and
total number of days that antibiotic(s) were administered
orally or intravenously, within 30 days prior to bacteraemia
(for VRE and VSE cases) or death or discharge (controls).
Data analyses were performed with Stata, version
12.0 (Stata Corporation, College Station, Texas, USA).
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Categorical variables are expressed as frequencies and
percentages. For continuous variables, mean or median
are reported for normally or non-normally distributed
data, respectively. Conditional logistic regression was
used to assess the association between each independ-
ent variable and the presence or absence of VRE or
VSE bacteraemia. We assessed the assumption of a
linear relationship between log odds and each of the
continuous exposure factors in the multivariable
models for VRE and VSE bacteraemia. The continuous
exposure factors were analysed as continuous variables
with coefficients expressed as odds ratio because the
relationships between log odds and each of the con-
tinuous exposure factors were approximately linear.
Variables that were significant on univariable analysis,
or biologically plausible factors linked to disease, or
potential confounders, were inserted into the multivar-
iable models. Link test was used to assess the fit of
each of the multivariable models for VRE and VSE bac-
teraemia [43]. All statistical tests were two-tailed and a
p < 0.05 was considered significant.
Results
Of the 724 patients with enterococcal bacteraemia iden-
tified during the study period, 121 (17%) and 603 (83%)
were VRE and VSE cases, respectively. A final number of
116 VRE cases (and corresponding matched VSE cases
and controls) were reviewed given four VRE patients
had missing medical records and one VRE patient was
pregnant. The ratio of enterococcal isolates that were
vancomycin-resistant to -susceptible was 6% in 2002,
and increased to 39% in 2009 and 22% in the first quar-
ter of 2010. All VRE isolates were vanB genotype.
Demographics of the VRE and VSE cases, and controls
are shown in Table 1. For the studied admission, the reason
for admission and co-morbidities were similar between
cases and controls. Most VRE isolates were Enterococcus
faecium, whereas the VSE isolates were predominantly E.
faecalis. To account for this difference, factors associated
with VSE bacteraemia due to E. faecium (haematological
malignancy and duration of neutropenia) and E. faecalis
(urinary catheter use) [44], were included in the multivari-
able analysis. We also accounted for time at risk for entero-
coccal bacteraemia by adjusting in the multivariable
analyses for the following factors occurring in the 30 days
prior to bacteraemia (for VRE and VSE cases) and death or
discharge (for controls): number of days of antibiotic ad-
ministration, neutropenia and hypoalbuminaemia, and use
of medical devices (e.g. catheters). Adjustment for age was
performed on multivariable analysis when age was found to
be significant on univariable analysis.
In patients with vanB VRE bacteraemia, 54 (47%), 22
(19%) and 14 (12%) were treated with teicoplanin mono-
therapy, linezolid monotherapy and no antibiotics,
respectively. For 26 (22%) vanB VRE bacteraemia
patients, a combination (concurrent or in sequence) of
teicoplanin, linezolid, quinupristin-dalfopristin or ben-
zylpenicillin was administered as definitive therapy. In
VSE patients, 46 (40%), 21 (18%), 1 (1%), 9 (8%), 6
(5%), and 2 (2%) patients were administered definitive
therapy using intravenous glycopeptides (teicoplanin
or vancomycin), penicillins (ampicillin, benzylpenicil-
lin, ticarcillin-clavulanic acid, piperacillin-tazobactam),
meropenem, no antibiotics, combination of intraven-
ous gentamicin and ampicillin, and oral linezolid, re-
spectively. In 30 (26%) VSE patients, a combination
(concurrent or in sequence) of vancomycin, teicopla-
nin, linezolid, ampicillin, benzylpenicillin or merope-
nem was administered.
Tables 2 and 3 summarise the analyses of factors
linked to VRE and VSE bacteraemia, respectively. In the
multivariable analysis, a higher CDS-VRE score, an in-
crease in duration of metronidazole therapy, and use of
urinary catheters within the previous 30 days were asso-
ciated with increased odds of vanB VRE bacteraemia
(Table 2). When patients with VSE bacteraemia were
compared to controls (Table 3), after adjustment for
confounders, admission to the haematology/oncology unit
(compared to non-haematology/oncology units) was associ-
ated with lower odds of VSE bacteraemia whilst, gastro-
intestinal disease and duration of metronidazole use were
associated with higher odds of VSE bacteraemia.
Discussion and conclusions
Unlike earlier studies [4,23,25-27], the current study
only included data from patients who had vanB VRE
bacteraemia and did not assess colonised patients. It is
not a single-centre study [4,9-12,15-27,30,31] and, to our
knowledge, is the largest case-case-control study involving
vanB VRE bacteraemia. The present report is the only
case-case-control study to identify the factors associated
with vanB VRE and VSE bacteraemia, while adjusting for
patient co-morbidities and duration of antibiotic therapy,
hypoalbuminaemia, and neutropenia.
The association between patient co-morbidities, as mea-
sured by the CDS-VRE score, and development of vanB
VRE bacteraemia was investigated. The CDS-VRE score
was calculated based on medications ordered within
24 hours of hospital admission for medical conditions such
as diabetes, peptic ulcers, kidney disease, history of trans-
plantation and cancer [42]. A weight is assigned for
each medical condition and the final CDS-VRE score is a
weighted sum of the medical conditions for each patient.
The presence of a higher number of co-morbidities
included in the score is associated with a higher CDS-VRE
score. Co-morbidities related to immune-suppression such
as transplantation and cancer were given a higher weight-
ing, compared to diabetes and peptic ulcer. As such,
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patients with co-morbidities associated with immune-
suppression tend to have high CDS-VRE scores. Our results
show that patients with a higher CDS-VRE score have
higher odds for vanB VRE bacteraemia. This was consistent
with studies that reported association between haemato-
logical malignancy and vanA VRE bacteraemia [11]. Dia-
betes [20], acute renal failure [19], and severity of gut
mucositis [18] may predispose patients to the development
of VRE bacteraemia; VRE genotype was not determined in
these studies.
Antibiotic use has been linked to VRE colonisation in
the gastrointestinal tract and/or infection, including
bacteraemia [19,26,45]. In the present study, duration of
therapy with specific antibiotics was considered, unlike












Male 69 (59) 72 (62) 63 (54)
Female 47 (41) 44 (38) 53 (46)
Unit of admission
Haematology/oncology 61 (53) 43 (37) 67 (58)
Non-haematology/oncology 55 (47) 73 (63) 49 (42)
Reason for admission
Medical 89 (77) 87 (75) 89 (77)
Surgical 27 (23) 29 (25) 27 (23)
Charlson score, median (IQR) 4 (2–5) 3 (1–5) 4 (1–4)
Chronic disease score-VRE (CDS-VRE), median (IQR) 1 (0–1.9) 0 (0–1) 0 (0–1.6)
Lung disease 17 (15) 17 (15) 17 (15)
Ischaemic heart disease 25 (22) 23 (20) 11 (9)
Myocardial infarction 10 (9) 10 (9) 3 (3)
Congestive heart failure 13 (11) 14 (12) 2 (2)
Cerebrovascular disease 7 (6) 13 (11) 5 (4)
Gastrointestinal disease 54 (47) 64 (55) 38 (33)
Renal disease 21 (18) 18 (16) 15 (13)
Diabetes mellitus 25 (22) 30 (26) 20 (17)
Cancer 74 (64) 64 (55) 74 (64)
Solid organ transplant recipient 14 (12) 7 (6) 5 (4)
Enterococcus species
E. faecalis 9 (8) 71 (61) -
E. faecium 107 (92) 39 (34) -
E. casseliflavus, E. gallinarum, or E. durans - 4 (3) -
Both E. faecalis and E. faecium - 1 (1) -
Unknown - 1 (1) -
Polymicrobial bacteraemia 33 (28) 50 (43) -
Infection (other than due to Enterococci) prior to bacteraemia (VRE and VSE cases) and prior to discharge
(controls)
61 (53) 43 (37) 34 (29)
Days from admission until bacteraemia, median (IQR), days 16 (7–24) 7.5 (1–18.5) -





In-hospital mortality 42 (36) 30 (26) 5 (4)
Note:
Data are number (%) of patients unless indicated otherwise.
Percentages were rounded to the nearest whole number.
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many earlier studies [12,13,16,17,19-22,24,27,28,30]. Ex-
posure to anti-anaerobic antibiotics has been linked to
VRE gastrointestinal tract colonisation [45] and bacter-
aemia [10,46]; however, the VRE genotype was either
vanA VRE [10,46] or not determined [45]. In our study,
an increase in duration of therapy with metronidazole
(an anti-anaerobic antibiotic) was linked to VRE bacter-
aemia. Whilst exposure to metronidazole may be a
marker for bacteraemia with suspected intra-abdominal
source, this was not explored as it was beyond the scope
of the current work. A recent study reported an associ-
ation between increased ceftriaxone usage and VRE
bacteraemia (genotype not reported) [29]. An association
with ceftriaxone therapy, however, was not observed in
our study which adjusted for patient co-morbidities.
Although VRE overgrowth and subsequent VRE colon-
isation and/or infection may occur with vancomycin
exposure [11,13], multivariable analysis suggests that the
use of vancomycin was not associated with increased
odds of VRE bacteraemia in this study. This is probably
Table 2 Factors associated with vanB VRE bacteraemia





OR 95% CI p-value OR 95% CI p-value
Age, median (IQR), years 60 (47–68) 58 (44–68) 1.01 0.99-1.02 0.481
Female 47 (41) 53 (46) 0.81 0.48-1.36 0.432
Transfer from another hospital 28 (24) 14 (12) 2.56 1.18-5.52 0.017
Unit of admission
Non-haematology/oncology to read Non-haematology/oncology 55 (47) 49 (42) Reference
Haematology/oncology 61 (53) 67 (58) 0 - -
ICU admission in prior 30 days 39 (34) 13 (11) 6.57 2.97-14.55 <0.001
CDS-VRE score, median (IQR) 1 (0–1.9) 0 (0–1.6) 1.36 1.02-1.80 0.036 1.70 1.05-2.77 0.032
Clostridium difficile toxin positive 5 (4) 1 (1) 5.00 0.58-42.80 0.142
Infection(s) due to pathogens other than Enterococci 61 (53) 34 (29) 2.93 1.60-5.37 0.001 0.97 0.39-2.46 0.953
Gastrointestinal disease 54 (47) 38 (33) 2.00 1.10-3.64 0.024
Liver disease 16 (14) 15 (13) 1.14 0.41-3.15 0.796
Haematological malignancy 66 (57) 63 (54) 1.6 0.52-4.89 0.410 0.41 0.06-2.61 0.342
Bone marrow transplantation type
Nil 97 (84) 100 (86) Reference Reference
Autologous 3 (3) 7 (6) 0.33 0.07-1.65 0.178 0.27 0.03-2.22 0.221
Allogeneic 16 (14) 9 (8) 2.40 0.85-6.81 0.100 2.79 0.57-13.66 0.206
Ceftriaxone days, median (IQR), days 0 (0) 0 (0) 1.09 0.98-1.22 0.130 1.16 0.91-1.48 0.234
Third generation cephalosporin days , median (IQR), daysa 0 (0–1) 0 (0–0.49) 1.04 0.95-1.13 0.439
Fluoroquinolone days, median (IQR), daysb 1 (0–7.63) 0 (0–2.42) 1.07 1.01-1.12 0.016
Metronidazole days, median (IQR), days 0 (0–1.78) 0 (0) 1.54 1.16-2.04 0.003 1.65 1.17-2.33 0.004
Ticarcillin-clavulanic acid days, median (IQR), days 0 (0) 0 (0) 1.02 0.92-1.13 0.674
Piperacillin-tazobactam days, median (IQR), days 0 (0–2.18) 0 (0) 1.04 0.96-1.14 0.352
Meropenem days, median (IQR), days 0 (0–5.94) 0 (0) 1.15 1.06-1.25 0.001
Vancomycin days, median (IQR), days 2.58 (0–8) 0 (0–2.18) 1.10 1.04-1.17 0.002 1.04 0.95-1.15 0.401
Neutropenia days, median (IQR), days 1 (0–10) 0 (0–1) 1.08 1.03-1.14 0.003 1.04 0.96-1.11 0.341
Hypoalbuminaemia days, median (IQR), days 13 (7.5-20) 5.5 (2–14.5) 1.08 1.04-1.12 <0.001 0.97 0.91-1.04 0.435
Central line use 94 (81) 55 (47) 5.22 2.56-10.66 <0.001 3.06 0.94-9.99 0.063
Mechanical ventilation 29 (25) 7 (6) 5.40 2.08-14.02 0.001
Urinary catheter 57 (49) 27 (23) 3.50 1.84-6.65 <0.001 2.86 1.09-7.53 0.033
Parenteral nutrition 28 (24) 8 (7) 3.86 1.68-8.86 0.001
Note:
Data are number (%) of patients unless indicated otherwise.
aThird generation cephalosporins include cefotaxime, ceftriaxone, and ceftazidime.
bFluoroquinolones include moxifloxacin, norfloxacin and ciprofloxacin.
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due to a reduction in bias [33,47] as the present study
did not use VSE as controls, in contrast to studies that
had included VSE patients as controls [11,13]. In this
study, the controls without enterococcal bacteraemia
have had exposure to vancomycin. Thus, a comparison
of VRE to VSE bacteraemia patients could be made to
identify factors linked to VRE bacteraemia; however, we
chose to compare VRE bacteraemia patients to controls
without enterococcal bacteraemia in a case-case–control
study as it will minimise the selection bias that affects
the identification, and the magnitude, of the effect due
to vancomycin [33,47]. To further minimise selection
bias related to choice of controls in the current study,
VSE patients and controls were randomly chosen and
matched to VRE cases for time of admission and wher-
ever possible, unit of admission.
Similar to studies that demonstrated VRE bacteraemia
was associated with exposure of patients to VRE con-
taminated ‘exogenous’ sources [16,31], urinary catheter
use was independently associated with the development
Table 3 Factors associated with VSE bacteraemia





OR 95% CI p-value OR 95% CI p-value
Age, median (IQR), years 63.5 (51–76) 58 (44–68) 1.02 1.00-1.04 0.019 1.01 0.99-1.03 0.305
Female 44 (38) 53 (46) 0.74 0.44-1.23 0.243
Transfer from another hospital 21 (18) 14 (12) 1.64 0.77-3.46 0.198
Unit of admission
Non-haematology/oncology to read Non-haematology/oncology 73 (63) 49 (42) Reference Reference
Haematology/oncology 43 (37) 67 (58) 0.04 0.01-0.30 0.002 0.08 0.01-0.74 0.026
ICU admission in prior 30 days 29 (25) 13 (11) 2.60 1.25-5.39 0.010 1.71 0.52-5.58 0.373
CDS-VRE score, median (IQR) 0 (0–1) 0 (0–1.6) 0.89 0.66-1.20 0.446
Clostridium difficile toxin positive 2 (2) 1 (1) 2.00 0.18-22.06 0.571
Infection(s) due to pathogens other than Enterococci 43 (37) 34 (29) 1.45 0.82-2.56 0.201
Gastrointestinal disease 64 (55) 38 (33) 3.00 1.60-5.62 0.001 2.29 1.05-4.99 0.037
Liver disease 13 (11) 15 (13) 0.71 0.23-2.25 0.566
Haematological malignancy 35 (30) 63 (54) 0.15 0.06-0.39 <0.001 0.40 0.12-1.33 0.134
Bone marrow transplantation type
Nil 105 (91) 100 (86) Reference Reference
Autologous 2 (2) 7 (6) 0.29 0.06-1.38 0.118
Allogeneic 9 (8) 9 (8) 1.00 0.38-2.66 1.000
Ceftriaxone days, median (IQR), days 0 (0–0.5) 0 (0) 1.10 0.99-1.24 0.088
Third generation cephalosporin days , median (IQR), daysa 0 (0–1) 0 (0–0.49) 1.03 0.94-1.13 0.523
Fluoroquinolone days, median (IQR), daysb 0 (0–1.04) 0 (0–2.42) 0.96 0.91-1.02 0.190
Metronidazole days, median (IQR), days 0 (0) 0 (0) 1.23 1.06-1.43 0.007 1.23 1.02-1.48 0.032
Ticarcillin-clavulanic acid days, median (IQR), days 0 (0) 0 (0) 1.02 0.93-1.11 0.711
Piperacillin-tazobactam days, median (IQR), days 0 (0) 0 (0) 0.89 0.79-1.00 0.054
Meropenem days, median (IQR), days 0 (0) 0 (0) 1.00 0.92-1.08 0.934
Vancomycin days, median (IQR), days 0 (0–1.25) 0 (0–2.18) 0.97 0.92-1.03 0.343
Neutropenia days, median (IQR), days 0 0 (0–1) 0.98 0.94-1.02 0.344 1.00 0.94-1.06 0.911
Hypoalbuminaemia days, median (IQR), days 7 (1–16) 5 (1–13.5) 1.01 0.98-1.05 0.479 1.00 0.95-1.05 0.888
Central line use 59 (51) 55 (47) 1.17 0.67-2.05 0.572
Mechanical ventilation 17 (15) 7 (6) 2.67 1.04-6.81 0.040
Urinary catheter 46 (40) 27 (23) 2.12 1.19-3.77 0.011 1.16 0.47-2.88 0.741
Parenteral nutrition 16 (14) 8 (7) 2.00 0.86-4.67 0.109
Note:
Data are number (%) of patients unless indicated otherwise.
aThird generation cephalosporins include cefotaxime, ceftriaxone, and ceftazidime.
bFluoroquinolones include moxifloxacin, norfloxacin and ciprofloxacin.
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of VRE bacteraemia. The need for a urinary catheter
may also be an indicator of severe underlying illness
[16]. Compared to an earlier study that only considered
hypoalbuminaemia and neutropenia in a binary manner
(i.e. presence or absence) [31], in the present study the
durations of these conditions were found to be linked to
VRE bacteraemia. The use of a continuous variable (i.e.
duration) provides a more robust measure of exposure
to these potential factors linked to disease.
The duration of metronidazole therapy was linked to
VSE bacteraemia, similar to our finding for vanB VRE
bacteraemia. However, other factors linked to disease
differed between these two types of bacteraemia. We
found that a history of gastrointestinal disease was asso-
ciated with VSE bacteraemia. Changes in the gastrointes-
tinal tract may predispose to the migration of gut micro-
organisms such as enterococci, increasing the link to
VSE bacteraemia [48]. Due to the difficulty in matching
VSE cases to VRE cases from the haematology/oncology
unit, we adjusted for unit of admission in the multivari-
able analysis for VSE bacteraemia. Interestingly, admis-
sion to the haematology/oncology unit compared to
other units was associated with reduced odds of VSE
bacteraemia. This finding may be due to an unmeasured
confounder such as exposure in this group of patients to
antibiotics that are active against VSE, thereby reducing
the odds of VSE bacteraemia. Unlike earlier studies that
did not adjust for duration of hypoalbuminaemia and
neutropenia [31,38], the present study found no associ-
ation between the duration of low albumin and neutro-
phil levels, and odds of VSE bacteraemia.
Through this case-case–control study we were able to
differentiate the factors associated with VRE and VSE
bacteraemia. It is recognised that data collected retro-
spectively may be subject to variability in reporting from
different clinicians and missing data. Whilst the effect of
individual enterococcal species on the results of this
study was not specifically studied given the sample size,
the potential effects of enterococcal species on study
findings were accounted for in the analysis. Failure to
adjust for confounding may result in falsely elevated
or reduced odds ratio [49]. Accordingly, multivariable
analyses were also performed in the current study to
minimise bias associated with confounding.
This study, the largest published case-case–control study
involving only vanB VRE bacteraemia has identified and
differentiated the factors associated with vanB VRE and
VSE bacteraemia. VSE bacteraemia was linked to a history
of gastrointestinal disease. In contrast, a higher burden of
patient co-morbidities and urinary catheter use were associ-
ated with vanB VRE bacteraemia.
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